Slide 1: Meet AZN Management: ADA 2026
Meet AZN Management: ADA 2026 Conference call and webcast for investors and analysts 8 June 2026 1
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Meet AZN Management @ ADA – agenda
Meet AZN Management @ ADA – agenda Furthering the AstraZeneca ambition with Ruud Dobber, EVP, BioPharmaceuticals Business weight management Elecoglipron – Phase II VISTA Vanita R. Aroda, MD elecoglipron in overweight or obesity Director, Diabetes Clinical Research, Brigham and Women’s Hospital Eleco
Slide 4: Furthering the AstraZeneca ambition with weight management
Furthering the AstraZeneca ambition with weight management Ruud Dobber EVP, BIOPHARMACEUTICALS BUSINESS 4
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after" ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 surovatamig camizestrant saruparib Next-g
Slide 6: Sustained weight management is essential for CVRM organ protection
Sustained weight management is essential for CVRM organ protection Underlying Multi-organ Obesity is a catalyst of interconnected diseases Risk factors effects incl. conditions Insulin Chronic kidney Obesity and overweight increases CVRM risk resistance disease Chronic liver Obesity Fluid retention
Slide 7: AZ commercial expertise to capitalise on significant global unmet need in weight management
AZ commercial expertise to capitalise on significant global unmet need in weight management Obesity is a growing global epidemic Global CVRM experience and infrastructure Expected global population with overweight or obesity by 2035 1 to meet global demand Built $8.5bn global Farxiga franchise US Ex
Slide 8: Elecoglipron – Phase IIb VISTA
Elecoglipron – Phase IIb VISTA Vanita R. Aroda, MD Director, Diabetes Clinical Research, Brigham and Women’s Hospital Associate Professor of Medicine, Harvard Medical School 8
Slide 9: VISTA: Phase IIb study design
Elecoglipron in adults with obesity or overweight VISTA: Phase IIb Study design 5 mg elecoglipron 5 mg no titration n = 32 Study population: 15 mg elecoglipron 15 mg no titration n = 49 ≥18 years of age Follow Up n=310 50 mg elecoglipron 50 mg titration n = 50 (4 wk steps) BMI ≥30 kg/m2 or Randomisa
Slide 10: VISTA: Baseline characteristics
VISTA: Baseline characteristics elecoglipron Mean age Pooled 5 mg 15 mg 50 mg q4wt 75 mg qwt 75 mg q2wt placebo Total N = 32 N = 49 N = 50 N = 49 N = 49 N = 81 N = 310 Body weight, kg, mean (SD) 107.5 (20.7) 109.7 (21.6) 104.4 (20.8) 106.7 (27.5) 103.5 (28.1) 108.7 (24.2) 106.9 (24.1) 48.4 years BMI
Slide 11: Clinically meaningful and statistically significant weight loss at week 26, further increasing to week 36
Clinically meaningful and statistically significant weight loss at week 26, further increasing to week 36 Percent change in body weight from BL to Week 26 and 36 2 Week 26 Week 36 Placebo-corrected 0 -0.3 percent change @ wk 36 -0.6 % change from BL in BW, -2 -2.6 -2.7 -2.4 (-5.4, 0.6) LS mean (95%
Slide 12: Significant proportion of patients achieved weight loss of at least 5% at weeks 26 and 36
Significant proportion of patients achieved weight loss of at least 5% at weeks 26 and 36 Weight loss ≥5% at week 26 Weight loss ≥5% at week 36 Weight loss ≥10% at week 36 Weight loss ≥15% at week 36 100 100 100 100 89 86 85 Proportion of participants (%) 80 76 77 80 80 80 73 62 63 60 60 56 60 60 51
Slide 13: Elecoglipron demonstrated clinically meaningful improvements in cardiometabolic risk factors
Elecoglipron demonstrated clinically meaningful improvements in cardiometabolic risk factors SBP (mmHg) | BL mean 125 mmHg DBP (mmHg) | BL mean 81 mmHg 10 4 1.5 2 LS mean (95%CI) 5 change from BL LS mean (95%CI) change from BL 0 0 -2 -5 -4 -1.2 -1.5 -6 -10 -3.2 -2.8 -4.0 -8 -4.7 -8.1 -8.2 -8.8 -15 -
Slide 14: Safety profile of elecoglipron is consistent with the GLP-1 receptor agonist class
Safety profile of elecoglipron is consistent with the GLP-1 receptor agonist class elecoglipron Pooled 5 mg 15 mg 50 mg q4wt 75 mg qwt 75 mg q2wt placebo Events, n (%) N = 32 N = 49 N = 50 N = 49 N = 49 N = 81 Any AEs 27 (84) 43 (87.8) 44 (88.0) 48 (98.0) 45 (91.8) 68 (84.0) Any SAEs 0 0 0 4 (8.2) 4
Slide 15: Gastrointestinal effects were most common adverse event and mild to moderate
Gastrointestinal effects were most common adverse event and were of mild to moderate severity elecoglipron Pooled 5 mg 15 mg 50 mg q4wt 75 mg qwt 75 mg q2wt placebo Events, n (%) N = 32 N = 49 N = 50 N = 49 N = 49 N = 81 Any GI AE 17 (53.1) 38 (77.6) 40 (80.0) 41 (83.7) 38 (77.6) 42 (51.9) Nausea 3
Slide 16: No liver safety signals were observed in VISTA
No liver safety signals were observed in VISTA Participants with ALT, AST or total bilirubin ≥3xULN, emerging post randomisation elecoglipron Pooled 5 mg 15 mg 50 mg q4wt 75 mg qwt 75 mg q2wt placebo n (%) N = 32 N = 49 N = 50 N = 49 N = 49 N = 81 ALT 0 0 0 2 (4.1) 0 1 (1.3) AST 0 0 1 (2.0) 0 0 0 To
Slide 17: Dose dependent reductions in ALT were observed
Dose dependent reductions in ALT were observed ALT change from baseline (on-treatment) BL mean 25.7 U/L 5 Mean change from baseline (SEM), U/L 0 -5 -10 -15 -20 0 BL 4 8 12 16 20 24 28 32 36 Week Placebo elecoglipron 15 mg elecoglipron 75 mg qwt elecoglipron 5 mg elecoglipron 50 mg q4wt elecoglipron
Slide 18: VISTA Phase IIb demonstrates elecoglipron's potential to treat obesity and its related complications
VISTA Phase IIb demonstrates elecoglipron’s potential to treat obesity and its related complications Daily oral elecoglipron demonstrated clinically meaningful weight reductions in adults living with obesity or overweight without T2D No indication of a plateau in weight loss was observed by 36 weeks
Slide 19: Elecoglipron – Phase IIb SOLSTICE
Elecoglipron – Phase IIb SOLSTICE Vanita R. Aroda, MD Director, Diabetes Clinical Research, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School 19
Slide 20: SOLSTICE: Phase IIb trial design
Elecoglipron in adults with type 2 diabetes SOLSTICE: Phase IIb trial design 5mg elecoglipron 5 mg Study population: 15mg elecoglipron 15 mg ≥18 years of age 25mg elecoglipron 25 mg Follow Up N=406 HbA1c 7.0%–10.5% 50mg elecoglipron 50 mg (2.5 mg initiation, 2-week dose escalation) T2D managed with
Slide 21: SOLSTICE: Baseline characteristics
SOLSTICE: Baseline characteristics Mean age elecoglipron Semaglutide 2.5 mg→ 5 mg→ 10 mg→ 3 mg→ 5 mg 15 mg 25 mg 50 mg q2wt 75 mg q2wt 75 mg q4wt Placebo 14 mg q4wt (n=38) (n=62) (n=41) (n=66) (n=37) (n=38) (n=71) (n=51) 58.4 years HbA1c, % 7.9 (1.0) 7.9 (1.0) 7.9 (1.0) 7.9 (0.9) 8.1 (1.1) 7.8 (1.0)
Slide 22: Elecoglipron demonstrated statistically significant and clinically meaningful reductions in HbA1c
Elecoglipron demonstrated statistically significant and clinically meaningful reductions in HbA1c 0.2 Mean BL HbA1c 7.9% Change from baseline in HbA1c, % -0.2 -0.2 Mean (95% CI) -0.6 -0.9 -1 -1.1 -1.2 -1.3 -1.4 -1.4 -1.6 -1.8 -1.9 -2.2 -2.6 BL 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) elecog
Slide 23: Majority of patients receiving 75mg achieved guideline recommended glycaemic targets
Majority of patients receiving 75mg elecoglipron achieved guideline recommended glycaemic targets 100 90 87 85 77 74 73 74 72 64 63 68 80 56 55 Proportion of participants (%) 60 39 40 25 13 20 0 <7.0%* ≤ 6.5% elecoglipron 5 mg elecoglipron 25 mg elecoglipron 75 mg q2wt Placebo (n = 38) (n = 41) (n =
Slide 24: Elecoglipron (doses ≥25 mg) achieved significantly greater weight reductions compared with placebo
Elecoglipron (doses ≥25 mg) achieved significantly greater reductions in weight compared with placebo 2 Mean BL body weight 99.9 kg Percent change from baseline in body 0 weight (%), Mean (95% CI) -1.7 -2 -2.9 -3.4 -4 -4.0 -5.1 -6 -5.9 -7.0 -8 -7.7 -10 BL 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (w
Slide 25: Elecoglipron demonstrated clinically meaningful improvements in cardiometabolic risk factors
Elecoglipron demonstrated clinically meaningful improvements in cardiometabolic risk factors Triglycerides (mg/dL) LDL-C calculated (mg/dL) hs-CRP (mg/L) 60 20 60 3 6 40 40 20 20 LS Mean (95% CI) LS Mean (95% CI) LS Mean (95% CI) change from BL change from BL change from BL 0 0 0 -20 -20 -40 -2 -20
Slide 26: Safety profile of elecoglipron is consistent with the GLP-1 receptor agonist class
Safety profile of elecoglipron is consistent with the GLP-1 receptor agonist class elecoglipron semaglutide 2.5 mg→ 5 mg→ 10 mg→ 3 mg→ 5 mg 15 mg 25 mg 50 mg q2wt 75 mg q2wt 75 mg q4wt Placebo 14 mg q4wt Events, n (%) N = 38 N = 62 N = 41 N = 66 N = 37 N = 38 N = 71 N = 51 Any AE 24 (63.2) 39 (62.9)
Slide 27: Gastrointestinal effects were most common adverse event and mild to moderate
Gastrointestinal effects were most common adverse event and were of mild to moderate severity elecoglipron semaglutide 2.5 mg→ 5 mg→ 10 mg→ 3 mg→ 5 mg 15 mg 25 mg 50 mg q2wt 75 mg q2wt 75 mg q4wt Placebo 14 mg q4wt Events, n (%) N = 38 N = 62 N = 41 N = 66 N = 37 N = 38 N = 71 N = 51 Nausea 1 (2.6)
Slide 28: No liver safety signals were observed in SOLSTICE
No liver safety signals were observed in SOLSTICE Participants with ALT, AST or total bilirubin ≥3xULN, emerging post randomisation elecoglipron semaglutide 2.5 mg→ 5 mg→ 10 mg→ 3 mg→ 5 mg 15 mg 25 mg 50 mg q2wt 75 mg q2wt 75 mg q4wt Placebo 14 mg q4wt n (%) N = 38 N = 62 N = 41 N = 66 N = 37 N = 38
Slide 29: Dose dependent reductions in ALT were observed
Dose dependent reductions in ALT were observed ALT change from baseline (on-treatment) 5 0 -0.1 baseline (SEM), U/L Mean change from -0.1 -4.0 -5 -5.8 -6.8 -7.0 -9.3 -10 -9.8 -15 0BL 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) elecoglipron 5 mg elecoglipron 25 mg elecoglipron 75 mg q2wt Placebo
Slide 30: SOLSTICE Phase IIb shows potential for elecoglipron to become important treatment for patients with T2D
SOLSTICE Phase IIb shows potential for elecoglipron to become important treatment for patients with T2D Daily oral elecoglipron achieved clinically meaningful and statistically significant HbA1c and fasting glucose reductions across all doses Up to 90% of participants receiving elecoglipron achieved
Slide 31: Elecoglipron as foundation of AZ weight management portfolio
Elecoglipron as foundation of AZ weight management portfolio Mikhail Kosiborod SVP, LATE CVRM R&D 31
Slide 32: Phase II VISTA and SOLSTICE trials demonstrate elecoglipron's potential as multi-blockbuster asset
Phase II VISTA and SOLSTICE trials demonstrate elecoglipron’s potential as multi-blockbuster asset Clinically meaningful weight Favourable safety profile Convenient small molecule loss and glycaemic control1 10.5% weight loss at GI tolerability consistent No food or fluid dosing week 26 with GLP-1 R
Slide 33: Ambitious Phase III programme designed to deliver broad outcome benefits starting H2 2026
Ambitious Phase III programme designed to deliver broad outcome benefits starting H2 2026 Patients with obesity or Patients with type 2 diabetes Outcomes trials with overweight Elecoglipron ± dapagliflozin elecoglipron on background Elecoglipron monotherapy of dapagliflozin + other SoC Multiple tria
Slide 34: Weight management portfolio built to address diverse patient needs
Weight management portfolio built to address diverse patient needs Less than 5% of eligible patients with obesity receive treatment today1 PATIENT NEED SOLUTION ASTRAZENECA ASSET elecoglipron (oGLP-1 RA) Ph32 Obesity / overweight +/- comorbidities Oral, no fasting eleco combinations Ph2 GLP-1 intole
Slide 35: Delivering CVRM growth into 2030 and beyond
Delivering CVRM growth into 2030 and beyond Sharon Barr EVP, BIOPHARMACEUTICALS R&D 35
Slide 36: Broad-based CVRM pipeline with multiple high-value pipeline assets
Broad-based CVRM pipeline with multiple high-value pipeline assets which address key interrelated diseases Dyslipidaemia Heart failure Weight Hypertension and amyloidosis Kidney disease management Liver disease and ASCVD and diabetes laroprovstat baxdrostat eplontersen balcinrenone/dapa elecoglipron
Slide 37: Exciting CVRM portfolio with franchises launching by 2030
Exciting CVRM portfolio with 5 franchises launching by 2030 balci/dapa, elecoglipron, eleco FDCs, laroprovstat zibo/dapa, AZD6234, baxdro/dapa AZD9550 UNCONTROLLED AND ATTR-CM DYSLIPIDAEMIA CARDIO-RENAL WEIGHT MANAGEMENT TREATMENT RESISTANT FRANCHISE FRANCHISE HYPERTENSION $5bn+1 $5bn+ 1 $5bn+ 1 $5b
Slide 38: Closing Remarks and Q&A Session
Closing Remarks and Q&A Session Key External Expert Vanita R. Aroda, MD DIR EC TOR , D IABET ES C LINICAL RE SE AR CH, B RIG HAM AND WO ME N’S HOSPIT AL ASSOC IAT E PROF ESSO R OF MED ICINE, HAR VAR D MED ICAL SCH OOL AstraZeneca Leadership Pascal Soriot Ruud Dobber E VP, BIOPH AR MACEUT ICALS CH IE
Slide 39: Appendix
Appendix 39
Slide 40: Glossary
Glossary ADA American Diabetes Association IO immuno-oncology ADC antibody-drug conjugate IRA Inflation Reduction Act AE adverse event LDL-C low-density lipoprotein cholesterol ALT alanine aminotransferase LSM least-squares mean APOL1 apolipoprotein L1 M&A mergers and acquisitions ASCVD atherosclero
Slide 41: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis